Durability of the First Antiretroviral Treatment Regimen and Reasons for Change in Patients With HIV Infection

REFERENCES

• Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17–26.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Enferm lnfecc Microbiol Clin. 2012;30(6):e1–89.
   PubMedGoogle Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing pat-terns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352(9142): 1725–1730.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS. 200115(2):185–194.
   Google Scholar
• De La Torre J, Santos J, Perea-Milla E, et al. Primera pauta de tratamiento antirretroviral en pacientes con infecci6n por el VIH. Durabilidad y factores asociados a su modifi-cación. Enferm lnfecc Microbiol Clin. 2008;26(7):416–422.
   PubMed Web of Science ®Google Scholar
• Bae JW, Guyer W, Grimm K, Altice FL. Medication per-sistence in the treatment of HIV infection: A review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–290.
   PubMed Web of Science ®Google Scholar
• Martin MT, Rovira M, Massanes M, et al. Analisis de la duraci6n y los motivos de cambio de la primera com-binaci6n de tratamiento antirretroviral. Farm Hosp. 2010;34(5):224–230.
   PubMedGoogle Scholar
• Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003;37(5):714–722.
   PubMed Web of Science ®Google Scholar
• Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15)1 951–1960.
   Web of Science ®Google Scholar
• Vo TT, Ledergerber B, Keiser O, et al. Durability and out-come of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008;197(12):1685–1694.
   PubMed Web of Science ®Google Scholar
• Abgrall 5; The Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and N. America 2002-2009. AIDS. 2013;27:803–813.
   PubMed Web of Science ®Google Scholar
• Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010;170(1):57–65.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Cavassini M, Battegay M, et al. Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Med. 2011;12(5):279–288.
   PubMed Web of Science ®Google Scholar
• Smit M, Smit C, Cremin I, Garnett GP, Hallett T, de WF. Could better tolerated HIV drug regimens improve patient outcome? AIDS. 2012 26(15):1953–1959.
   PubMed Web of Science ®Google Scholar
• Juday T, Grimm K, Zoe-Powers A, Willig J, Kim E. A retro-spective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care. 2011;23(9)1154–1162.
   Web of Science ®Google Scholar
• Di Biagio A, Prinapori R, Giannarelli D, et al. Duration of first-line antiretroviral therapy with tenofovir and emtric-itabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. J Antimicrob Chemother. 2013;68(1):200–205.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Arici C, Airoldi M, et al. Reasons for discon-tinuation of nevirapine-containing HAART: Results from an unselected population of a large clinical cohort. J Antimi-crob Chemother. 2007;59(3):569–572.
   PubMed Web of Science ®Google Scholar
• Reekie J, Reiss P, Ledergerber B, et al. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: A EuroSIDA study. HIV Med. 2011;12(5):259–268.
   PubMed Web of Science ®Google Scholar
• d’Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiret-roviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14(5):499–507.
   PubMed Web of Science ®Google Scholar
• Jarrin I, Hernandez-Novoa B, Alejos B, et al. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008–2010 [published online ahead of print September 20,2012]. Antivir Ther.
   Web of Science ®Google Scholar
• Prosperi MC, Fabbiani M, Fanti I, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infect Dis. 201212: 296.
   Google Scholar
• Yuan Y, L’italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–162.
   PubMed Web of Science ®Google Scholar
• Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104–113.
   PubMed Web of Science ®Google Scholar
• Robison LS, Westfall AO, Mugavero MJ, et al. Short-term discontinuation of HAART regimens more common in vul-nerable patient populations. AIDS Res Hum Retroviruses. 2008;24(11):1347–1355.
   PubMed Web of Science ®Google Scholar
• Park WB, Choe PG, Kim SH, et al. Early modification of initial HAART regimen associated with poor clinical outcome in HIV patients. AIDS Res Hum Retroviruses. 2007;23(6):794–800.
   PubMed Web of Science ®Google Scholar
• Ribeiro FA, Tupinambas U, Fonseca MO, Greco DB. Dura-bility of the first combined antiretroviral regimen in patients with AIDS at a reference center in Belo Horizonte, Brazil, from 1996 to 2005. Braz J Infect Dis. 2012;16(1):27–33.
   PubMed Web of Science ®Google Scholar
• Domingo P, Suarez-Lozano I, Torres F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: The SUSKA study, a non-randomized comparison from the VACH cohort. J Antimi-crob Chemother. 2008;61(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Willig JH, Aban I, Nevin CR, et al. Darunavir outcomes study: Comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks. AIDS Res Hum Retroviruses. 2010;26(12):1279–1285.
   PubMed Web of Science ®Google Scholar